Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
June 09, 2022 07:35 ET
|
Olema Oncology
Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansionCombinability with CDK4/6i palbociclib demonstrated across initial dose...
Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies
June 09, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, June 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) and Aurigene Discovery Technologies Limited (“Aurigene”) today announced an...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, June 02, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology to Present at Jefferies Healthcare Conference
May 24, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, May 24, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 16:30 ET
|
Olema Oncology
Phase 1/2 trial of OP-1250 continues to enroll patients in the dose expansion stage, with selection of Recommended Phase 2 Dose expected in Q2 2022Phase 1b combination study with palbociclib ongoing;...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
April 04, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief...
Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08, 2022 16:35 ET
|
Olema Oncology
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...